Morgan Stanley Raises Amgen Price Target on Obesity Drug Potential

Morgan Stanley has revised its price target for Amgen upward, citing positive developments in the company's obesity treatment drug development efforts. The investment bank increased its per-share price target after assessing Amgen's potential in this area. Analysts noted that Amgen's obesity drug portfolio, particularly its clinical-stage candidates, could significantly contribute to the company's growth prospects. The rapid expansion of the obesity drug market may enhance Amgen's competitive position in this segment. Morgan Stanley's report emphasized that Amgen's existing drug portfolio and innovative treatments in its R&D pipeline support the company's long-term value. Advances in the obesity space, in particular, strengthen Amgen's potential to diversify and grow its revenues. This price target upgrade reflects confidence in Amgen's market performance. Investors are closely monitoring the company's milestones in obesity drug development and regulatory approval processes. This is not investment advice.